PaxMedica, Inc. (NASDAQ:PXMD – Get Rating)’s share price fell 3.6% during mid-day trading on Tuesday . The stock traded as low as $2.30 and last traded at $2.38. 190,469 shares were traded during trading, a decline of 24% from the average session volume of 251,516 shares. The stock had previously closed at $2.47.
PaxMedica Stock Down 3.6 %
The company’s fifty day moving average price is $1.98.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in PaxMedica stock. Jane Street Group LLC acquired a new stake in PaxMedica, Inc. (NASDAQ:PXMD – Get Rating) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 18,025 shares of the company’s stock, valued at approximately $43,000. Jane Street Group LLC owned approximately 0.15% of PaxMedica as of its most recent filing with the SEC.
PaxMedica Company Profile
PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT).
- Get a free copy of the StockNews.com research report on PaxMedica (PXMD)
- Mobileye Expects $17.5 Billion Future For Its Driver Assist Tech
- Is Salesforce’s New Rally The Beginning Of A Big Uptrend?
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.